Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 20% ± 5% | |
macrophage | 9 studies | 24% ± 6% | |
mast cell | 7 studies | 22% ± 11% | |
type I pneumocyte | 6 studies | 18% ± 3% | |
basal cell | 6 studies | 26% ± 5% | |
classical monocyte | 6 studies | 26% ± 8% | |
mesothelial cell | 6 studies | 23% ± 5% | |
epithelial cell | 5 studies | 27% ± 6% | |
retinal ganglion cell | 4 studies | 45% ± 28% | |
ciliated cell | 4 studies | 24% ± 4% | |
regulatory T cell | 4 studies | 16% ± 1% | |
respiratory goblet cell | 3 studies | 24% ± 5% | |
secretory cell | 3 studies | 26% ± 3% | |
conventional dendritic cell | 3 studies | 25% ± 8% | |
neuron | 3 studies | 19% ± 3% | |
club cell | 3 studies | 19% ± 1% | |
GABAergic neuron | 3 studies | 42% ± 5% | |
glutamatergic neuron | 3 studies | 49% ± 8% | |
dendritic cell | 3 studies | 26% ± 11% | |
microglial cell | 3 studies | 21% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2671.13 | 1445 / 1445 | 100% | 24.20 | 183 / 183 |
lung | 100% | 4160.29 | 578 / 578 | 100% | 21.55 | 1155 / 1155 |
breast | 100% | 3813.65 | 459 / 459 | 100% | 37.80 | 1116 / 1118 |
stomach | 100% | 2169.41 | 359 / 359 | 99% | 15.75 | 284 / 286 |
thymus | 100% | 2775.00 | 653 / 653 | 99% | 14.72 | 598 / 605 |
ovary | 100% | 3256.33 | 180 / 180 | 99% | 15.59 | 425 / 430 |
bladder | 100% | 3100.43 | 21 / 21 | 99% | 16.26 | 498 / 504 |
uterus | 100% | 2736.84 | 170 / 170 | 99% | 16.94 | 453 / 459 |
intestine | 100% | 3085.11 | 966 / 966 | 99% | 13.71 | 520 / 527 |
prostate | 100% | 3961.51 | 245 / 245 | 98% | 18.55 | 494 / 502 |
kidney | 100% | 3121.09 | 89 / 89 | 98% | 16.76 | 882 / 901 |
liver | 100% | 2688.77 | 226 / 226 | 98% | 16.82 | 397 / 406 |
pancreas | 100% | 2207.15 | 328 / 328 | 98% | 16.20 | 174 / 178 |
skin | 100% | 4074.69 | 1809 / 1809 | 94% | 15.70 | 445 / 472 |
adrenal gland | 100% | 2524.71 | 258 / 258 | 88% | 8.42 | 203 / 230 |
brain | 97% | 2203.34 | 2553 / 2642 | 80% | 6.82 | 562 / 705 |
adipose | 100% | 4133.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 6502.84 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.96 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.92 | 1 / 1 |
blood vessel | 100% | 2648.99 | 1332 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 3674.81 | 919 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 3465.52 | 846 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 9.85 | 27 / 29 |
eye | 0% | 0 | 0 / 0 | 79% | 7.59 | 63 / 80 |
muscle | 71% | 620.78 | 570 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1904977 | Biological process | lymphatic endothelial cell migration |
GO_0098586 | Biological process | cellular response to virus |
GO_0098792 | Biological process | xenophagy |
GO_0005615 | Cellular component | extracellular space |
GO_0005829 | Cellular component | cytosol |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
GO_0005178 | Molecular function | integrin binding |
Gene name | LGALS8 |
Protein name | Galectin Galectin-8g Alternative protein LGALS8 Galectin 8 Galectin-8 (Gal-8) (Po66 carbohydrate-binding protein) (Po66-CBP) (Prostate carcinoma tumor antigen 1) (PCTA-1) |
Synonyms | |
Description | FUNCTION: Beta-galactoside-binding lectin that acts as a sensor of membrane damage caused by infection and restricts the proliferation of infecting pathogens by targeting them for autophagy . Detects membrane rupture by binding beta-galactoside ligands located on the lumenal side of the endosome membrane; these ligands becoming exposed to the cytoplasm following rupture . Restricts infection by initiating autophagy via interaction with CALCOCO2/NDP52 . Required to restrict infection of bacterial invasion such as S.typhimurium . Also required to restrict infection of Picornaviridae viruses . Has a marked preference for 3'-O-sialylated and 3'-O-sulfated glycans . . |
Accessions | ENST00000526634.5 [O00214-1] E9PJ77 B3F166 ENST00000416919.6 Q96QS7 ENST00000481485.5 ENST00000526589.5 [O00214-2] ENST00000442397.6 E9PRN3 ENST00000525042.1 ENST00000434231.6 O00214 ENST00000238181.11 ENST00000430527.6 ENST00000450372.6 [O00214-2] L8E9E9 E9PPL1 ENST00000529489.5 ENST00000323938.10 F6V2D4 Q5T3P9 ENST00000352231.6 [O00214-2] H7BXD8 ENST00000454943.6 B1ANM0 E9PNC2 E9PPM4 ENST00000527974.5 [O00214-2] ENST00000341872.10 [O00214-1] E9PN19 ENST00000406509.7 ENST00000366584.9 [O00214-1] |